Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
Dysfunction of the ubiquitin-proteasome system (UPS) and accumulation of iron in substantia nigra (SN) are implicated in the pathogenesis of Parkinson's disease (PD). UPS dysfunction and iron misregulation may reinforce each other's contribution to the degeneration of dopamine (DA) neurons. In the present study, we use a new brain-permeable iron chelator, VK-28 [5-(4-(2-hydroxyethyl) piperazin-1-yl (methyl)-8-hydroxyquinoline], and its derivative M30 [5-(N-methyl-N-propargyaminomethyl)-8-hydroxyquinoline] in vivo to test their neuroprotective and neurorestorative properties against proteasome inhibitor (lactacystin) -induced nigrostriatal degeneration. Bilateral microinjections of lactacystin (1.25 microg/side) into the mouse medial forebrain bundle were performed. Administration of VK-28 (5 mg/kg, once a day) or M30 (5 mg/kg, once a day) was applied intraperitoneally 7 days before or after the lactacystin microinjection until the mice were sacrificed 28 days after microinjection. We found that VK-28 and M30 both significantly improved behavioral performances and attenuated lactacystin-induced DA neuron loss, proteasomal inhibition, iron accumulation, and microglial activation in SN. In addition, M30 restored the Bcl-2 level, which was suppressed after lactacystin injection. These findings suggest that brain-permeable iron chelators can improve DA neuron survival under UPS impairment. Furthermore, M30, a derivative of VK-28 and neuroprotective agent rasagiline, may serve as a better neuroprotective therapy for PD.
Zhu
Wen
W
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
Xie
Wenjie
W
Pan
Tianhong
T
Xu
Pingyi
P
Fridkin
Mati
M
Zheng
Hailin
H
Jankovic
Joseph
J
Youdim
Moussa B H
MB
Le
Weidong
W
D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000633:toxicity; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006041:Goats; D006912:Hydroxyquinolines / Q000493:pharmacokinetics / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000517:prevention & control*; D009474:Neurons / Q000187:drug effects / Q000473:pathology*; D011817:Rabbits; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology*
C517687:5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline; D006912:Hydroxyquinolines; D007502:Iron Chelating Agents; C067713:lactacystin; D004298:Dopamine; D000111:Acetylcysteine